PubMed HealthSearch

Biomedical subjects

R R Olson

Publications and source records attributed to R R Olson.

4 recordsLinked to original sources

Mutations in the third, but not the first or second, hypervariable regions of DR(beta 1*0101) eliminate DR1-restricted recognition of a pertussis toxin peptide.

We have examined the role of 12 polymorphic residues of the beta-chain of the HLA-DR1 class II molecule in T cell recognition of an epitope of pertussis toxin. Murine L cell transfectants expressing wild-type or mutant DR1 molecules (containing single amino acid substitutions in DR(beta 1*0101)) were used as APC in proliferation assays involving nine DR1-restricted T cell clones specific for peptide 30-42 of pertussis toxin. Four different patterns of recognition of the mutants were found among the pertussis-specific clones. Residues in the third hypervariable region (HVR) of DR(beta 1*0101) are critically important for all the T cell clones; amino acid substitutions at positions 70 and 74 abrogated recognition by all of the T cell clones, and substitutions at positions 67 and 71 eliminated recognition by most of the clones. In contrast, most single amino acid substitutions in the first and second HVR, predicted to be located in the floor of the peptide binding groove, had little or no effect on the proliferative responses of these clones. However, the involvement of beta-chain first and second HVR residues was demonstrated by the inability of transfectants expressing wild-type DR(beta 1*0404) (DR4Dw14) or DR(beta 1*1402) (DR6Dw16) to present peptide to these clones. These beta-chains have completely different first and second HVR compared with DR(alpha,beta 1*0101) although the third HVR are identical. These results illustrate the functional importance of third HVR residues of DR(beta 1*0101) and allow definition of the molecular interactions of the DR1 molecule with the 30-42 peptide.

Amino Acid Sequence

Whose larvae?

Explore the source record for details and available documents.

Animals

CD5+ B lymphocytes in systemic lupus erythematosus and rheumatoid arthritis.

B lymphocytes which express the CD5 antigen on their cell surface have the ability to produce autoantibodies in vitro. We describe 2 patients, one with systemic lupus erythematosus and another with rheumatoid arthritis, whose percentages of peripheral blood CD5+ B lymphocytes were dramatically increased to 68 and 100%, respectively. A reduction of this subpopulation of B cells was associated with clinical improvement after therapy. This association suggests a relationship between CD5+ B cells and autoimmune disease activity.

Adult